Early research (Phase 1)WithdrawnNCT00803374What this trial is testingCombination of Anti-CD137 & Ipilimumab in Patients With MelanomaWho this might be right forMelanoma Bristol-Myers Squibb
Testing effectiveness (Phase 2)WithdrawnNCT01851408What this trial is testingSorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable MelanomaWho this might be right forMelanomaRecurrent MelanomaStage III Melanoma+1 more National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Study completedNCT00289640What this trial is testingStudy of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV MelanomaWho this might be right forMelanoma Bristol-Myers Squibb 210
Early research (Phase 1)Study completedNCT01489059What this trial is testingSafety Study of IL-21/Ipilimumab Combination in the Treatment of MelanomaWho this might be right forMelanoma Bristol-Myers Squibb 42
Large-scale testing (Phase 3)Study completedNCT00111007What this trial is testingA Treatment Combination for Patients With Unresectable Stage III or Stage IV MelanomaWho this might be right forMelanoma Bayer 270
Early research (Phase 1)WithdrawnNCT01843738What this trial is testingRadiation Use During Vemurafenib TreatmentWho this might be right forBRAFV600 MutationStage IV Melanoma University of Utah
Testing effectiveness (Phase 2)Study completedNCT00135408What this trial is testingMDX-010 (BMS-734016) Administered With or Without Prophylactic Oral BudesonideWho this might be right forMalignant Melanoma Bristol-Myers Squibb 115
Testing effectiveness (Phase 2)Ended earlyNCT06984328What this trial is testingStudy of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)Who this might be right forCutaneous MelanomaRelapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID)Metastatic Cutaneous Melanoma (Stage IV) Genmab 1
Testing effectiveness (Phase 2)Ended earlyNCT02587650What this trial is testingCapmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV MelanomaWho this might be right forALK Fusion Protein ExpressionBRAF wt AlleleInvasive Skin Melanoma+12 more University of California, San Francisco 1
Testing effectiveness (Phase 2)Study completedNCT00261365What this trial is testingPhase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)Who this might be right forUnresectable Stage III or IV Malignant Melanoma Bristol-Myers Squibb 80
Testing effectiveness (Phase 2)UnknownNCT00086866What this trial is testingVaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With SurgeryWho this might be right forMelanoma (Skin) European Organisation for Research and Treatment of Cancer - EORTC 165
Testing effectiveness (Phase 2)Ended earlyNCT02414750What this trial is testingVemurafenib Plus Cobimetinib in Metastatic MelanomaWho this might be right forMetastatic Melanoma Netherlands Working Group on Immunotherapy of Oncology 78
Testing effectiveness (Phase 2)Study completedNCT01950390What this trial is testingIpilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by SurgeryWho this might be right forStage IIIC Cutaneous Melanoma AJCC v7Stage IV Cutaneous Melanoma AJCC v6 and v7Unresectable Melanoma National Cancer Institute (NCI) 169
Testing effectiveness (Phase 2)Ended earlyNCT03325101What this trial is testingDendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable MelanomaWho this might be right forStage III Cutaneous Melanoma AJCC v7Stage IIIA Cutaneous Melanoma AJCC v7Stage IIIB Cutaneous Melanoma AJCC v7+2 more Mayo Clinic 7
Testing effectiveness (Phase 2)Ended earlyNCT01316692What this trial is testingAurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV MelanomaWho this might be right forRecurrent MelanomaStage IIIc MelanomaStage IV Melanoma Vanderbilt-Ingram Cancer Center 12
Testing effectiveness (Phase 2)Study completedNCT02902029What this trial is testingEvaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant MelanomaWho this might be right forMalignant Melanoma University Hospital, Essen 186
Early research (Phase 1)Ended earlyNCT03565406What this trial is testingA Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV MelanomaWho this might be right forMelanoma NYU Langone Health 11
Early research (Phase 1)Ended earlyNCT01409174What this trial is testingIPI Biochemotherapy for Chemonaive Patients With Metastatic MelanomaWho this might be right forMelanoma M.D. Anderson Cancer Center 19
Testing effectiveness (Phase 2)Ended earlyNCT04527549What this trial is testingTesting Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K MelanomaWho this might be right forClinical Stage IV Cutaneous Melanoma AJCC v8Locally Advanced MelanomaPathologic Stage IIIC Cutaneous Melanoma AJCC v8+2 more ECOG-ACRIN Cancer Research Group 5
Testing effectiveness (Phase 2)Active Not RecruitingNCT04356729What this trial is testingA Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic MelanomaWho this might be right forClinical Stage III Cutaneous Melanoma AJCC v8Stage IV MelanomaUnresectable Stage III Cutaneous Melanoma+1 more F. Stephen Hodi, MD 30